SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Unquoted Biotechs
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: nigel bates who wrote (30)1/15/2002 11:10:12 AM
From: Mike McFarland  Read Replies (1) of 253
 
<the Intronn approach to gene therapy is truly unique>

In Nature Biotech page 32 'Fooling Mother Nature'
Ronald Crystal writes "The strategy of correcting
mutations at the mRNA level is not new, nor is the
specific strategy of trans-splicing. Ribozymes have
been used for this purpose, as have antisense approaches."

I wondered aloud in the club.tgen thread on Yahoo if
AAV could carry the PTMs (they used Ad in the experiments).
And there are the non-viral lipid vectors.
So it seems to me that you come full circle.

I'll be lurking and hoping for remarks from our GT expert.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News